

# Key Investor Information



This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

## Baillie Gifford Worldwide Health Innovation Fund - Class A USD Shares

Accumulation Shares - ISIN IE00BKMG4D66

This Fund is a sub-fund of Baillie Gifford Worldwide Funds PLC.

### Objectives and investment policy

#### Objective

- The Fund aims to produce capital growth over the long term.

#### Policy

- To invest mainly in global equities selected from companies involved in the healthcare industry and which are innovative in their focus. The Fund will not be restricted to equity securities in the healthcare sector as defined by any particular index.

- Investment will be concentrated by the number of stocks held but diversified across a range of healthcare themes.

- The Fund is actively managed and no index is used for the purposes of determining or constraining the composition of the Fund's portfolio. The Fund's performance (after deduction of costs) is measured against the MSCI ACWI Index. In addition the Fund's performance (after deduction of costs) is measured against the MSCI ACWI Health Care Index. The Fund seeks to materially outperform the index.

#### Other Information

- You can sell some or all of your shares on any day on which banks in Ireland are open for business by contacting the Transfer Agent by phone or post.

- Income will be re-invested. No further shares will be purchased but the reinvestment will be reflected in the price of your existing accumulation shares.

- For further explanation and information see the investment objective and policy section of the Prospectus, which is available by contacting us.

- Recommendation: this Fund may not be appropriate for investors who plan to withdraw their money within five years.

### Risk and reward profile

The Risk and Reward Indicator table demonstrates where the Fund ranks in terms of its potential risk and reward. The higher the rank the greater the potential reward but the greater the risk of losing money. It is based on past data, may change over time and may not be a reliable indication of the future risk profile of the Fund. The shaded area in the table below shows the Fund's ranking on the Risk and Reward Indicator.

Typically lower rewards,  
lower risk

Typically higher rewards,  
higher risk



- Please note that even the lowest risk class can lose you money and that extreme adverse market circumstances can mean you suffer severe losses in all cases.
- The Fund is classified in the category above because it invests in company shares which generally provide higher rewards and higher risks than other investments such as bonds or cash. Where no share price history is available for any part of the last five years (and thus no returns), the returns of the Fund's comparative index is used in its place to calculate the Risk and Reward Indicator.
- The indicator does not take into account the following relevant material risks:
  - Investment markets can go down as well as up and market conditions can change rapidly. The value of an investment in the Fund, and any income from it, can fall as well as rise and you may not get back the amount invested.
  - The Fund has exposure to foreign currencies and changes in the rates of exchange will cause the value of any investment, and income from it, to fall as well as rise and you may not get back the amount invested.
  - Custody of assets, particularly in emerging markets, involves a risk of loss if a custodian becomes insolvent or breaches duties of care.
  - The Fund invests in emerging markets where difficulties in trading could arise, resulting in a negative impact on the value of your investment.
  - The Fund's concentrated portfolio relative to similar funds and in a particular geographical area or industry may result in large movements in the share price in the short term.
  - Infectious viruses may pose significant threats to human health and may be highly disruptive to global economies and markets. The economic and market disruptions caused by infectious viruses could impact the value of the investments of a Fund.

## Charges

The charges you pay are used to pay the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

### One-off charges taken before or after you invest

Entry charge	5.00%
Exit charge	0.00%

These are the maximum charges that we might take out of your money before it is invested and before we pay out the sale proceeds of your investment. In some cases, you might pay less and you should speak to your financial adviser about this.

### Charges taken from the Fund over a year

Ongoing charges	1.65%
-----------------	-------

### Charges taken from the Fund under specific conditions

Performance fee	NONE
-----------------	------

- The ongoing charges figure is based on the last year's expenses and may vary from year to year. It excludes the costs of buying or selling assets for the Fund (unless these assets are shares of another fund).
- For the ongoing charges, the figure is at 30/09/2020.
- The Fund's annual report for each financial year will include detail on the exact charges made.
- You can find further details about the charges in the fees and expenses section of the Prospectus, which is available by contacting us.

## Past performance

There is insufficient data to provide a useful indication of past performance to investors.

- Fund launch date: 01/10/2018.
- Share/unit class launch date: 02/03/2020.
- There can be no guarantee that the Fund's performance will match or exceed the performance of the index.

## Practical information

- The Fund's Custodian is Brown Brothers Harriman Trustee Services (Ireland) Limited. You can obtain further information on the Fund, the Prospectus and the latest annual and interim reports from Baillie Gifford or by visiting the website at [www.bailliegifford.com](http://www.bailliegifford.com). The remuneration policy, which includes details of (a) how remuneration and benefits are calculated and (b) the committee responsible for approving all remuneration policies within the firm, is also at the website address noted. All such documents are available in English, on paper and are free of charge on request. This Key Investor Information Document describes the Baillie Gifford Worldwide Health Innovation Fund only. The Prospectus and the annual and interim reports and accounts are prepared for the company. Baillie Gifford Worldwide Health Innovation Fund is a sub-fund of Baillie Gifford Worldwide Funds PLC. The assets of the sub-fund are segregated from other sub-funds in the company. This means that the assets of one sub-fund cannot be used to meet the liabilities of another sub-fund. The latest share prices are available from Brown Brothers Harriman Fund Administration Services (Ireland) Limited during normal business hours and from the Baillie Gifford website. Tax laws in Ireland may have an impact on your own tax position. You may at any time switch all or some of your shares in the Fund for shares in any sub-fund of the company and may obtain further information about this from the conversion of shares section of the Prospectus. Baillie Gifford Worldwide Funds PLC may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the Prospectus for the Fund. To contact us please call Brown Brothers Harriman Fund Administration Services (Ireland) Limited: 00-353-1-241-7156 (fax 00-353-1-241-7157) or visit the Baillie Gifford website at [www.bailliegifford.com](http://www.bailliegifford.com) for further information. For investors in Switzerland: The extract prospectus and the Key Investor Information Documents for Switzerland, the articles of association, the extract annual and semi-annual report in English, and further information can be obtained free of charge from the representative in Switzerland: UBS Fund Management (Switzerland) AG, Aeschenvorstadt 1, 4002 Basel. The Swiss paying agent is UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zurich. The last share prices can be found on [www.fundinfo.com](http://www.fundinfo.com).